U.S. flag

An official website of the United States government

NM_000371.4(TTR):c.114T>A (p.Asp38Glu) AND Cardiovascular phenotype

Germline classification:
Pathogenic (1 submission)
Last evaluated:
Apr 17, 2023
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV003299056.1

Allele description

NM_000371.4(TTR):c.114T>A (p.Asp38Glu)

Gene:
TTR:transthyretin [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
18q12.1
Genomic location:
Preferred name:
NM_000371.4(TTR):c.114T>A (p.Asp38Glu)
HGVS:
  • NC_000018.10:g.31592940T>A
  • NG_009490.1:g.6174T>A
  • NM_000371.3:c.114T>A
  • NM_000371.4:c.114T>AMANE SELECT
  • NP_000362.1:p.Asp38Glu
  • LRG_416t1:c.114T>A
  • LRG_416:g.6174T>A
  • NC_000018.9:g.29172903T>A
Protein change:
D38E
Links:
dbSNP: rs779619795
NCBI 1000 Genomes Browser:
rs779619795
Molecular consequence:
  • NM_000371.4:c.114T>A - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Cardiovascular phenotype
Identifiers:
MedGen: CN230736

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV003997333Ambry Genetics
criteria provided, single submitter

(Ambry General Variant Classification Scheme_2022)
Pathogenic
(Apr 17, 2023)
germlineclinical testing

PubMed (4)
[See all records that cite these PMIDs]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

A rare transthyretin mutation (Asp18Glu) associated with cardiomyopathy.

Connors LH, Yamashita T, Yazaki M, Skinner M, Benson MD.

Amyloid. 2004 Mar;11(1):61-6.

PubMed [citation]
PMID:
15185501

Genetic microheterogeneity of human transthyretin detected by IEF.

Altland K, Benson MD, Costello CE, Ferlini A, Hazenberg BP, Hund E, Kristen AV, Linke RP, Merlini G, Salvi F, Saraiva MJ, Singer R, Skinner M, Winter P.

Electrophoresis. 2007 Jun;28(12):2053-64.

PubMed [citation]
PMID:
17503405
See all PubMed Citations (4)

Details of each submission

From Ambry Genetics, SCV003997333.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (4)

Description

The p.D38E pathogenic mutation (also known as c.114T>A), located in coding exon 2 of the TTR gene, results from a T to A substitution at nucleotide position 114. The aspartic acid at codon 38 is replaced by glutamic acid, an amino acid with highly similar properties. This variant (also referred to as D18E) was reported to cause complete absence of protein when analyzed by electrophoresis detection method (Atland et al 2007. Electrophoresis 2007 Jun;28(12):2053-64). A patient presenting with cardiomyopathy due to amyloid deposits was reported with this pathogenic mutation (Connors LH et al. Amyloid 2004; 11:61-6). This mutation was further described in a patient who presented with vitreous deposits of amyloid and a significant family history of amyloidosis who developed further amyloid deposits and required a heart/kidney/liver transplant (Solano JM et al. Ophthalmic Genet. 2007; 28:73-5). Other alterations at the same codon, including p.D38N (c.112G>A), have also been reported in association with amyloidosis (Quarta CC & Falk RH. Amyloid. 2012;19(4):204-7). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Apr 15, 2024